Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients

被引:67
作者
Forlano, Rosario
Ippolito, Antonio Massimo
Iacobellis, Angelo
Merla, Antonio
Valvano, Maria Rosa
Niro, Grazia
Annese, Vito
Andriulli, Angelo [1 ]
机构
[1] IRCCS, Div Gastroenterol, Casa Sollievo della Sofferenza Hosp, San Giovanni Rotondo, Italy
关键词
UNITED-STATES; LIFE-STYLE; METAANALYSIS; OVERWEIGHT; SURGERY; INTERVENTIONS; SAFETY;
D O I
10.1016/j.gie.2009.06.036
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: In obese patients, positioning of the BioEnterics intragastric balloon (BIB) proved beneficial for weight loss, but the effect of the device on ameliorating some components of the metabolic syndrome associated with obesity remains uncertain. Objective: To evaluate the effectiveness of BIB insertion on weight control and amelioration of components of the metabolic syndrome. Design: A prospective intervention study performed at baseline, 6 months after BIB insertion, and after a mean (standard deviation [SD]) of 21 (3) months (range 14-26) of follow-up. Setting: Division of Gastroenterology and Endoscopic Unit, "Casa Sollievo della Sofferenza" Hospital. Patients: One hundred thirty obese patients with a mean (SD) weight of 118 (24) kg and mean (SD) body mass index (BMI) of 43 (8) kg/m(2). Interventions: Positioning of BIB. Main Outcome Measurements: Anthropometric and laboratory parameters. Results: Overall, the mean (SD) weight and BMI decreased by 13.2 (8.2) kg and 5.1 (3.2) kg/m(2), respectively, compared with baseline. The mean glycemia, insulinemia, Homeostasis Model Assessment index, triglyceridemia, and alanine aminotransferase levels were significantly reduced. In the 91 responders (BMI decrease of >= 3.5 kg/m(2)), the mean (SD) weight and BMI decreased by 16,4 (6.3) kg and 6.4 (2.3) kg/m(2), respectively, and severe liver steatosis decreased from 52% to 4% (P < .0001). On multivariate analysis, severe steatosis and the Homeostasis Model Assessment index were predictive of the response to BIB: odds ratios of 6.71 (95% CI, 2.23-20.19) and 3.18 (95% CI, 1.20-8.42). After a median follow-up of 22 months after BIB removal, 50% of responders maintained or continued to lose weight. Limitations: No sham-treated patients were included as comparative controls. Conclusions: Treatment was effective in inducing weight loss, improving liver steatosis, and restoring some components of the metabolic syndrome. (Gastrointest Endosc 2010;71:927-33.)
引用
收藏
页码:927 / 933
页数:7
相关论文
共 20 条
[1]   Population comparison of two clinical approaches to the metabolic syndrome - Implications of the new International Diabetes Federation consensus definition [J].
Adams, RJ ;
Appleton, S ;
Wilson, DH ;
Taylor, AW ;
Dal Grande, E ;
Chittleborough, C ;
Gill, T ;
Ruffin, R .
DIABETES CARE, 2005, 28 (11) :2777-2779
[2]  
AMMAR K, 2006, AM HEART J, V148, P277
[3]  
FERNANDES M, 2007, COCHRANE DB SYST REV, V24
[4]   Epidemiologic aspects of overweight and obesity in the United States [J].
Flegal, KM .
PHYSIOLOGY & BEHAVIOR, 2005, 86 (05) :599-602
[5]  
GRUNDY SM, 1991, ANN INTERN MED, V115, P956
[6]   Metabolic Obesity: The Paradox Between Visceral and Subcutaneous Fat [J].
Hamdy, Osama ;
Porramatikul, Sriurai ;
Al-Ozairi, Ebaa .
CURRENT DIABETES REVIEWS, 2006, 2 (04) :367-373
[7]   What becomes of patients one year after the intragastric balloon has been removed? [J].
Herve, J ;
Wahlen, CH ;
Schaeken, A ;
Dallemagne, B ;
Dewandre, JM ;
Markiewicz, S ;
Monami, B ;
Weerts, J ;
Jehaes, C .
OBESITY SURGERY, 2005, 15 (06) :864-870
[8]   Safety and effectiveness of the intragastric balloon for obesity.: A meta-analysis [J].
Imaz, Inaki ;
Martinez-Cervell, Carmen ;
Garcia-Alvarez, Elvira Elena ;
Sendra-Gutierrez, Juan Manuel ;
Gonzalez-Enriquez, Jesus .
OBESITY SURGERY, 2008, 18 (07) :841-846
[9]   Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin [J].
Knowler, WC ;
Barrett-Connor, E ;
Fowler, SE ;
Hamman, RF ;
Lachin, JM ;
Walker, EA ;
Nathan, DM .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (06) :393-403
[10]   Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up [J].
Mathus-Vliegen, EMH ;
Tytgat, GNJ .
GASTROINTESTINAL ENDOSCOPY, 2005, 61 (01) :19-27